JPX · 4556.T
KAINOS Laboratories, Inc.
¥2,268¥0 (0.0%)
KAINOS Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.7% below the high.
Loading market information…
JPX · 4892.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Cyfuse Biomedical K.K.’s quoted price sits in the lower half of its reported 52-week range, 26.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cyfuse Biomedical K.K.’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cyfuse Biomedical K.K.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥2,268¥0 (0.0%)
KAINOS Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.7% below the high.
¥2,550-¥11 (-0.43%)
WDB coco Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 9.73% below the high.
¥202-¥2 (-0.98%)
Precision System Science Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.44% below the high.
¥1,515¥0 (0.0%)
Nippon Chemiphar Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.42% below the high.
¥132+¥2 (+1.54%)
PRISM BioLab Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
¥59-¥2 (-3.28%)
D. Western Therapeutics Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.85% below the high.
¥28¥0 (0.0%)
Modalis Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 66.27% below the high.
¥142+¥2 (+1.43%)
Perseus Proteomics Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.24% below the high.
